For example, if the effect of ALG5 variant on uromodulin synthesis leads to CKD, the downregulation of uromodulin production could be a potential therapy for patients with ADPKD-ALG5 (as well as ADPKD-ALG8). Here, ALG5 is linked to autosomal dominant polycystic kidney disease.